There are chronic myeloid leukemia (CML) patients who show resistance to TKI therapy and are prone to progress to more advanced phases of the disease, and new therapeutic approaches are needed. Our study shows that CML cells are vulnerable to dihydroorotate dehydrogenase (DHODH) inhibition mediated by Meds433, a potent DHODH inhibitor developed by our group.
CML-164 Dihydroorotate Dehydrogenase Inhibition Reveals Metabolic Vulnerability in Chronic Myeloid Leukemia
Mulas, Olga;Caocci, Giovanni;
2022-01-01
Abstract
There are chronic myeloid leukemia (CML) patients who show resistance to TKI therapy and are prone to progress to more advanced phases of the disease, and new therapeutic approaches are needed. Our study shows that CML cells are vulnerable to dihydroorotate dehydrogenase (DHODH) inhibition mediated by Meds433, a potent DHODH inhibitor developed by our group.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
1-s2.0-S2152265022013660-main.pdf
accesso aperto
Dimensione
127.85 kB
Formato
Adobe PDF
|
127.85 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
